Johnson & Johnson

Yahoo Finance • 8 hours ago

Johnson & Johnson (JNJ): Evaluating Valuation Following Recent Share Price Gains

Johnson & Johnson (JNJ) shares have edged up roughly 0.4% since yesterday, continuing an upward stretch that has seen the stock climb 6% over the past month and 20% in the past three months. Investors are keeping an eye on how these steady... Full story

Yahoo Finance • 15 hours ago

Johnson & Johnson, Protagonist Therapeutics' Icotrokinra Shows Potential Across Autoimmune Indications, Wedbush Says

Icotrokinra, an oral interleukin-23 antagonist peptide being developed by Protagonist Therapeutics ( PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 17 hours ago

Why The Narrative Around J&J Is Shifting Amid Analyst Upgrades and Pharma Developments

Johnson & Johnson stock has recently seen its consensus analyst price target lifted from $179.64 to $185.13, marking an increase of approximately $5.49 as market sentiment improves. This upward revision comes as analysts anticipate renewed... Full story

Yahoo Finance • 19 hours ago

CG Oncology jumps as Guggenheim starts at Buy on potential against bladder cancer

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images CG Oncology (NASDAQ:CGON [https://seekingalpha.com/symbol/CGON]), a biotech focused on non-muscle invasive bladder cancer (NMIBC), traded ~9% higher on Wednesday after G... Full story

Yahoo Finance • yesterday

Johnson & Johnson (JNJ): A Cornerstone Among the Most Profitable Dividend Stocks

Johnson & Johnson (NYSE:JNJ) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now.Johnson & Johnson (JNJ): A Cornerstone Among the Most Profitable Dividend Stocks Johnson & Johnson (NYSE:JNJ) is one of America’s most... Full story

Yahoo Finance • 2 days ago

Legend Biotech, J&J ink Carvykti supply agreement

[Janssen Pharmaceuticals office in Brisbane, California, USA] JHVEPhoto/iStock Editorial via Getty Images * Legend Biotech (NASDAQ:LEGN [https://seekingalpha.com/symbol/LEGN]) and Johnson & Johnson's (NYSE:JNJ [https://seekingalpha.com/... Full story

Yahoo Finance • 2 days ago

LA County Jury Hits Johnson & Johnson with Nearly $1 Billion Verdict

Dean Omar Branham Shirley secures largest-ever mesothelioma talc verdict LOS ANGELES, October 07, 2025--(BUSINESS WIRE)--A Los Angeles County jury has returned damages totaling $966 million, including $950 million in punitive damages, to... Full story

Yahoo Finance • 2 days ago

Sector Update: Health Care Stocks Edge Down Late Afternoon

Health care stocks edged lower late Tuesday afternoon, with the NYSE Health Care Index and the Healt PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 days ago

J&J hit with $966M jury award in Los Angeles over talc-related cancer case

[Judges gavel in courtroom legal trial and law background] Johnson & Johnson (NYSE:JNJ [https://seekingalpha.com/symbol/JNJ]) will have to pay $966M after a jury in Los Angeles issued a verdict in favor of a woman who claimed that the pha... Full story

Yahoo Finance • 2 days ago

Prudential Financial (PRU): Assessing Valuation as Fundamental Challenges Draw Renewed Investor Scrutiny

Prudential Financial (PRU) has landed in the spotlight as investors take a closer look at its fundamentals. This follows news of shrinking net premiums, tepid book value growth, and a rising debt-to-equity ratio. See our latest analysis f... Full story

Yahoo Finance • 2 days ago

Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated with the highest dose achieving endoscopic improvement at Week 12 in the Phase 2b ANTHEM-UC study These data support the promise... Full story

Yahoo Finance • 2 days ago

TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis

Patients treated with subcutaneous TREMFYA® achieved clinically meaningful results in both clinical remission (36.7%) and endoscopic remission (25.9%) at Week 48 in the Phase 3 ASTRO study Clinical and endoscopic outcomes were demonstrate... Full story

Yahoo Finance • 2 days ago

Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses

Studies presented at #Academy25 reveal that ACUVUE OASYS MAX 1-Day for ASTIGMATISM outperformed Dailies Total1® for Astigmatism in patient reported outcomes related to vision and comfort. Research highlights that the latest ACUVUE contact... Full story

Yahoo Finance • 3 days ago

Diffuse Cutaneous Systemic Sclerosis Market Forecast: Opportunities and Growth Trends Upto 2034 | DelveInsight

DelveInsight Business Research LLP The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis and immune modulation, addressing a s... Full story

Yahoo Finance • 3 days ago

Did U.S. Orthopaedic Partners’ Medtech Deal Just Shift Johnson & Johnson’s (JNJ) Investment Narrative?

In the past week, U.S. Orthopaedic Partners announced a collaboration with Johnson & Johnson, selecting the medtech company as its official vendor for total joint products across its clinical platform after a surgeon-led evaluation of prod... Full story

Yahoo Finance • 3 days ago

Basil Systems Launches Safety Signaling Solution to Proactively Detect and Prevent Medical Device Risks

- Basil’s AI-powered Safety Signaling helps manufacturers identify risks associated with recalls, accelerate corrective actions, and strengthen patient safety. - Advanced MedTech intelligence platform already trusted by Johnson & Johnson,... Full story

Yahoo Finance • 4 days ago

Notable healthcare headlines for the week: Pfizer, Novo Nordisk and JNJ in focus

Wall Street’s broader market averages closed mixed on Friday as market participants digested the U.S. government shutdown for the third day. For the week, the Dow, S&P 500, and Nasdaq Composite advanced by 1.1%, 1.08%, and 1.32%, respecti... Full story

Yahoo Finance • 5 days ago

Jim Cramer Believes Lawsuits Are No Longer a Major Threat to Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer put under the microscope. Cramer recalled his discussion with the company’s CEO, and commented: “What else might work? Last Friday on the show, we had Joaquin Duato. He’s the CE... Full story

Yahoo Finance • 5 days ago

Pfizer – TrumpRx deal boosts Big Pharma to a record rally

[President Trump Delivers An Announcement From The Oval Office] Win McNamee/Getty Images News The world’s biggest pharma companies recorded their best weekly performance in years on Friday after Pfizer (NYSE:PFE [https://seekingalpha.com/... Full story

Yahoo Finance • 5 days ago

Notable analyst calls this week: J&J, PayPal and Corteva among top picks

The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]) closed in the green on Friday, while Nasdaq (COMP:IND [https://seekingalpha.... Full story